Wells Fargo
XLO icon

Wells Fargo’s Xilio Therapeutics XLO Stock Holding History

Wells Fargo’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8
Closed -$117 – 7540
2024
Q1 		$117 Hold
8
– – ﹤0.01% 6617
2023
Q4 		$58 Buy
8
+1
+14% +$20 ﹤0.01% 6901
2023
Q3 		$211 Buy
7
+1
+17% +$37 ﹤0.01% 6568
2023
Q2 		$212 Hold
6
– – ﹤0.01% 6686
2023
Q1 		$247 Hold
6
– – ﹤0.01% 6718
2022
Q4 		$207 Buy
6
+1
+20% +$34 ﹤0.01% 6614
2022
Q3 		$0 Buy
5
+1
+25% +$39 ﹤0.01% 7488
2022
Q2 		$0 Sell
4
-115
-97% -$6.08K ﹤0.01% 7612
2022
Q1 		$12K Sell
119
-200
-63% -$31.6K ﹤0.01% 6217
2021
Q4 		$71K Buy
+319
New +$76.1K ﹤0.01% 5802

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Wells Fargo's XLO Position: Q2 2024 in Review

Wells Fargo sold out of Xilio Therapeutics (XLO) in Q2 2024, closing a stake of 8 shares — an estimated $117 sold.

Wells Fargo first reported a position in XLO in Q4 2021 and held it in 10 quarters. The position peaked at $71K in Q4 2021. 31 funds tracked by Wall St. Rank hold XLO as of Q2 2024.

  • Wells Fargo reported no remaining Xilio Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 8 Xilio Therapeutics shares in Q2 2024, an estimated $117.
  • Wells Fargo first reported a position in Xilio Therapeutics in Q4 2021 and held it in 10 quarters.
  • Wells Fargo's Xilio Therapeutics position peaked at $71K in Q4 2021.
  • 31 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.